MSD
Key AGGRASTA® Studies
References
  1. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.

  2. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q-wave myocardial infarction.
    N Engl J Med 1998;338:1488–1497.

  3. Cannon CP, Weintraub WS, Demopoulos LA et al, for the TACTICS (Treat Angina with AGGRASTAT and Determine Cost of Therapy with an Invasive or Conservative Strategy)—Thrombolysis In Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879–1887.

  4. Blazing MA, de Lemos JA, White HD et al. Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non–ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA 2004;292(1):55–64. Erratum in: JAMA 2004;292(10):1178.

  5. Cohen M, Théroux P, Borzak S et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non–ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II Study. Am Heart J 2002;144:470–477.

  6. Bovill EG, Terrin ML, Stump DC et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115(4):256–265.
AGGRASTAT is a registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA